Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Merck
Dow
Baxter
Harvard Business School

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; NORGESTIMATE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ethinyl Estradiol; Norgestimate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00236769 A Study of Efficacy and Safety With the Transdermal Contraceptive System. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 1997-11-01 The purpose of the study is to evaluate the contraceptive efficacy, safety, cycle control, and compliance with the transdermal contraceptive system.
NCT00254865 A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2002-08-01 The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment.
NCT00301587 A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives Withdrawn Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 1969-12-31 The purpose of this study is to compare red blood cell folate levels in women who are taking oral contraceptives with or without folic acid
NCT00320567 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. Phase 2 1969-12-31 The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
NCT00331071 Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks Completed Boston Collaborative Drug Surveillance Program N/A 2002-04-01 The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases.
NCT00331071 Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. N/A 2002-04-01 The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ethinyl Estradiol; Norgestimate

Condition Name

Condition Name for Ethinyl Estradiol; Norgestimate
Intervention Trials
Contraception 8
Female Contraception 5
Pharmacokinetics 5
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ethinyl Estradiol; Norgestimate
Intervention Trials
HIV Infections 3
Hepatitis C 2
Acne Vulgaris 2
Venous Thromboembolism 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ethinyl Estradiol; Norgestimate

Trials by Country

Trials by Country for Ethinyl Estradiol; Norgestimate
Location Trials
United States 12
Canada 1
New Zealand 1
Netherlands 1
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ethinyl Estradiol; Norgestimate
Location Trials
Texas 3
Kansas 2
Washington 2
California 2
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ethinyl Estradiol; Norgestimate

Clinical Trial Phase

Clinical Trial Phase for Ethinyl Estradiol; Norgestimate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ethinyl Estradiol; Norgestimate
Clinical Trial Phase Trials
Completed 23
Enrolling by invitation 1
Suspended 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ethinyl Estradiol; Norgestimate

Sponsor Name

Sponsor Name for Ethinyl Estradiol; Norgestimate
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 9
Bristol-Myers Squibb 5
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ethinyl Estradiol; Norgestimate
Sponsor Trials
Industry 28
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Harvard Business School
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.